---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134759"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:13:53.765691+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS

## Summary
- FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.
- Phase 1b/2 palazestrant + ribociclib: median PFS not reached at 12-month follow-up.
- 6-month PFS rate 73% overall, 81% in ESR1 mutant patients, 68% after prior CDK4/6i.
- ORR 27% (10/37) in measurable disease; 76% CBR overall.
- Combination well tolerated with no new safety signals; plans for Phase 3 OPERA-02 in 2025.

## SEC filing metadata
- accession: 0000950170-24-134759
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/0000950170-24-134759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/olma-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134759
- JSON: https://secwatch.observer/filing/0000950170-24-134759.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.